Staff Publications: June 2017

  1. Adelstein D, Gillison ML, Pfister DG, et al. Nccn Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017;15(6):761-770. PMID: 28596256.
  2. Al-Ashmawy AAK, Ragab FA, Elokely KM, et al. Design, Synthesis and Sar of New-Di-Substituted Pyridopyrimidines as Atp-Competitive Dual Pi3kalpha/Mtor Inhibitors. Bioorg Med Chem Lett. 2017;27(14):3117-3122. PMID: 28571824.
  3. Alexander J, Cukierman E. Stromal Dynamic Reciprocity in Cancer: Intricacies of Fibroblastic-Ecm Interactions. Curr Opin Cell Biol. 2016;42:80-93. PMID: 27214794. PMC5064819. NIHMS786085.
  4. Alford RF, Leaver-Fay A, Jeliazkov JR, et al. The Rosetta All-Atom Energy Function for Macromolecular Modeling and Design. Journal of Chemical Theory and Computation. 2017;13(6):3031-3048.
  5. Ali N, Kutikov A, Geynisman DM. Resolution of a Debilitating Paraneoplastic Parkinson-Like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal Cell Carcinoma. Urol Case Rep. 2017;14:18-20. PMID: 28660133. PMC5479944.
  6. Al-Khalifa SE, Jennings MC, Wuest WM, Minbiole KP. The Development of Next-Generation Pyridinium-Based Multiqac Antiseptics. ChemMedChem. 2017;12(4):280-283. PMID: 28033453.
  7. Blaauwgeers H, Flieder D, Warth A, et al. A Prospective Study of Loose Tissue Fragments in Non-Small Cell Lung Cancer Resection Specimens: An Alternative View to “Spread through Air Spaces”. Am J Surg Pathol. 2017. PMID: 28622180.
  8. Borgmann H, Katz MS, Catto J, Weight C, Kutikov A. Quantification of Urology Related Twitter Traffic Activity through a Standardized List of Social Media Communication Descriptors. Urology Practice. 2017;4(4):349-354.
  9. Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage Iv or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(25):2415-2426. PMID: 28636851.
  10. Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-Based Phase Ii Trial of Savolitinib in Patients with Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017:Jco2017722967. PMID: 28644771.
  11. De Bari B, Stish B, Ball MW, et al. Adult Prostatic Sarcoma: A Contemporary Multicenter Rare Cancer Network Study. Prostate. 2017;77(10):1160-1166. PMID: 28594087.
  12. Deihimi S, Lev A, Slifker M, et al. Brca2, Egfr, and Ntrk Mutations in Mismatch Repair-Deficient Colorectal Cancers with Msh2 or Mlh1 Mutations. Oncotarget. 2017;8(25):39945-39962. PMID: 28591715.
  13. Edelman MJ, Hu C, Le QT, et al. Randomized Phase Ii Study of Preoperative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage Iiia, N2+) Non-Small Cell Lung Cancer: Nrg Oncology Rtog 0839. J Thorac Oncol. 2017. PMID: 28629896.
  14. Erkmen CP, Mitchell M, Randhawa S, et al. An Enhanced Shared Decision Making Model to Address Willingness and Ability to Undergo Lung Cancer Screening and Follow-up Treatment in Minority Underserved Populations. J Community Health. 2017. PMID: 28612174.
  15. Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376(23):2211-2222. PMID: 28591523.
  16. Gallego-Villar L, Hannibal L, Haberle J, et al. Cysteamine Revisited: Repair of Arginine to Cysteine Mutations. J Inherit Metab Dis. 2017. PMID: 28643139.
  17. Ge Y, Kier BL, Andersen NH, Voelz VA. Computational and Experimental Evaluation of Designed Beta-Cap Hairpins Using Molecular Simulations and Kinetic Network Models. J Chem Inf Model. 2017. PMID: 28614661.
  18. Gokare P, El-Deiry WS. The Tuberous Sclerosis Complex Gets Fatter. Oncotarget. 2017;8(26):41780-41781. PMID: 28611315.
  19. Goldstein LJ, Zhao F, Wang M, et al. A Phase I/Ii Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her2-Amplified Breast Cancer: A Trial of the Ecog-Acrin Cancer Research Group (E1104). Breast Cancer Res Treat. 2017. PMID: 28623430.
  20. Hahn NM, Bivalacqua TJ, Ross AE, et al. A Phase Ii Trial of Dovitinib in Bcg-Unresponsive Urothelial Carcinoma with Fgfr3 Mutations or Overexpression: Hoosier Cancer Research Network Trial Hcrn 12-157. Clinical Cancer Research. 2017;23(12):3003-3011.
  21. Hensley ML, Patel SR, von Mehren M, et al. Efficacy and Safety of Trabectedin or Dacarbazine in Patients with Advanced Uterine Leiomyosarcoma after Failure of Anthracycline-Based Chemotherapy: Subgroup Analysis of a Phase 3, Randomized Clinical Trial. Gynecol Oncol. 2017. PMID: 28651804.
  22. Herts BR, Silverman SG, Hindman NM, et al. Management of the Incidental Renal Mass on Ct: A White Paper of the Acr Incidental Findings Committee. J Am Coll Radiol. 2017. PMID: 28651987.
  23. Hou P, Wu C, Wang Y, et al. A Genome-Wide Crispr Screen Identifies Genes Critical for Resistance to Flt3 Inhibitor Ac220. Cancer Res. 2017. PMID: 28625976.
  24. Hurwitz MD, Harris J, Sartor O, et al. Adjuvant Radiation Therapy, Androgen Deprivation, and Docetaxel for High-Risk Prostate Cancer Postprostatectomy: Results of Nrg Oncology/Rtog Study 0621. Cancer. 2017;123(13):2489-2496.
  25. Jaffe EK. New Protein Structures Provide an Updated Understanding of Phenylketonuria. Mol Genet Metab. 2017. PMID: 28645531.
  26. Jamal N, Ebersole B, Erman A, Chhetri D. Maximizing Functional Outcomes in Head and Neck Cancer Survivors: Assessment and Rehabilitation. Otolaryngol Clin North Am. 2017. PMID: 28606600.
  27. Jiang W, Dulaimi E, Devarajan K, et al. Intratumoral Heterogeneity Analysis Reveals Hidden Associations between Protein Expression Losses and Patient Survival in Clear Cell Renal Cell Carcinoma. Oncotarget. 2017;8(23):37423-37434.
  28. Judd J, Zibelman M, Handorf E, et al. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist. 2017. PMID: 28652280.
  29. Kim SP, Campbell SC, Gill I, et al. Collaborative Review of Risk Benefit Trade-Offs between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. Eur Urol. 2017;72(1):64-75.
  30. Kruger WD. Cystathionine Beta-Synthase Deficiency: Of Mice and Men. Mol Genet Metab. 2017;121(3):199-205. PMID: 28583326.
  31. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for Brca1 and Brca2 Mutation Carriers. Jama. 2017;317(23):2402-2416. PMID: 28632866.
  32. Kuchenbaecker KB, McGuffog L, Barrowdale D, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in Brca1 and Brca2 Mutation Carriers. J Natl Cancer Inst. 2017;109(7). PMID: 28376175. PMC5408990.
  33. Liu T, Kan XF, Ma C, et al. Gpx2 Overexpression Indicates Poor Prognosis in Patients with Hepatocellular Carcinoma. Tumour Biol. 2017;39(6):1010428317700410. PMID: 28635398.
  34. Lu W, Liu Y, Ma H, et al. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-D]Pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. ACS Chem Neurosci. 2017. PMID: 28618224.
  35. Menzel LP, Chowdhury HM, Masso-Silva JA, et al. Potent in Vitro and in Vivo Antifungal Activity of a Small Molecule Host Defense Peptide Mimic through a Membrane-Active Mechanism. Sci Rep. 2017;7(1):4353. PMID: 28659617.
  36. Mortazavi SMJ, Mortazavi G, Paknahad M. Phase Down of Amalgam. Awareness of Minamata Convention among Jordanian Dentists. Saudi Medical Journal. 2017;38(5):560.
  37. Mortazavi SMJ, Mortazavi SAR. Auricular Hematoma Cases Caused by Mobile Phones. Oral and Maxillofacial Surgery Cases. 2017;3(3):54-55.
  38. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 2.2017: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017;15(6):804-834.
  39. Necchi A, Mariani L, Lo Vullo S, et al. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-Based Analysis. European Urology Focus. 2017.
  40. Pal SK, Ali SM, Yakirevich E, et al. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma Via Comprehensive Genomic Profiling. Eur Urol. 2017. PMID: 28592388.
  41. Papadopoulos KP, Gluck L, Martin LP, et al. First-in-Human Study of Amg 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017. PMID: 28655795.
  42. Prinsep MR, Appleton TG, Hanson GR, et al. Tolyporphin Macrocycles from the Cyanobacterium Tolypothrix Nodosa Selectively Bind Copper and Silver and Reverse Multidrug Resistance. Inorganic Chemistry. 2017;56(10):5577-5585.
  43. \Razavi AM, Delemotte L, Berlin JR, Carnevale V, Voelz VA. Molecular Simulations and Free-Energy Calculations Suggest Conformation-Dependent Anion Binding to a Cytoplasmic Site as a Mechanism for Na+/K+-Atpase Ion Selectivity. J Biol Chem. 2017. PMID: 28588025.
  44. Terry MB, Keegan THM, Houghton LC, et al. Pubertal Development in Girls by Breast Cancer Family History: The Legacy Girls Cohort. Breast Cancer Res. 2017;19(1):69. PMID: 28595647. PMC5465536.
  45. van Tuyn J, Jaber-Hijazi F, MacKenzie D, et al. Oncogene-Expressing Senescent Melanocytes Upregulate Mhc Class Ii, a Candidate Melanoma Suppressor Function. J Invest Dermatol. 2017. PMID: 28647344.
  46. Wang HH, Deng L, Wen QL, et al. Early Postoperative Radiotherapy Is Associated with Improved Outcomes over Late Postoperative Radiotherapy in the Management of Completely Resected (R0) Stage Iiia-N2 Non-Small Cell Lung Cancer. Oncotarget. 2017. PMID: 28599290.
  47. Williams RM, Tagai EK, Santos SLZ, Slade JL, Carter RL, Holt CL. The Role of Leadership Support in a Church-Based Cancer Education Implementation Study. J Relig Health. 2017. PMID: 28597333.
  48. Winckworth-Prejsnar K, Nardi EA, Lentz LK, Crawford JA, Fitzgerald CL, Carlson RW. Developments in Molecular Testing and Biosimilars. J Natl Compr Canc Netw. 2017;15(6):772-782. PMID: 28596257.
  49. Zaorsky NG, Davis BJ, Nguyen PL, et al. The Evolution of Brachytherapy for Prostate Cancer. Nat Rev Urol. 2017;14(7):415-439. PMID: 28664931.
  50. Zibelman M, Plimack ER. Integrating Immunotherapy into the Management of Renal Cell Carcinoma. J Natl Compr Canc Netw. 2017;15(6):841-847. PMID: 28596263.
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s